References
Key articles
Silvestry FE, Cohen MS, Armsby LB, et al. Guidelines for the echocardiographic assessment of atrial septal defect and patent foramen ovale: from the American Society of Echocardiography and Society for Cardiac Angiography and Interventions. J Am Soc Echocardiogr. 2015 Aug;28(8):910-58.Full text Abstract
Meier B, Kalesan B, Mattle HP, et al. Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med. 2013 Mar 21;368(12):1083-91. Abstract
Reference articles
1. Homma S, Sacco RL, Di Tullio MR, et al. Effect of medical treatment in stroke patients with patent foramen ovale: Patent Foramen Ovale in Cryptogenic Stroke Study. Circulation. 2002 Jun 4;105(22):2625-31.Full text Abstract
2. Dubiel M, Bruch L, Schmehl I, et al. Migraine headache relief after percutaneous transcatheter closure of interatrial communications. J Interv Cardiol. 2008 Feb;21(1):32-7.Full text Abstract
3. Roxas-Timonera M, Larracas C, Gersony D, et al. Patent foramen ovale presenting as platypnea-orthodeoxia: diagnosis by transesophageal echocardiography. J Am Soc Echocardiogr. 2001 Oct;14(10):1039-41. Abstract
4. Wilmshurst PT, Byrne JC, Webb-Peploe MM. Relation between interatrial shunts and decompression sickness in divers. Lancet. 1989 Dec 2;2(8675):1302-6. Abstract
5. Fisher DC, Fisher EA, Budd JH, et al. The incidence of patent foramen ovale in 1,000 consecutive patients. A contrast transesophageal echocardiography study. Chest. 1995 Jun;107(6):1504-9. Abstract
6. Thompson T, Evans W. Paradoxical embolism. Q J Med. 1930 Jan 1;23(90):135-52.
7. Hagen PT, Scholz DG, Edwards WD. Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts. Mayo Clin Proc. 1984 Jan;59(1):17-20. Abstract
8. Gupta V, Yesilbursa D, Huang WY, et al. Patent foramen ovale in a large population of ischemic stroke patients: diagnosis, age distribution, gender, and race. Echocardiography. 2008 Feb;25(2):217-27. Abstract
9. Rodriguez CJ, Homma S, Sacco RL, et al. Race-ethnic differences in patent foramen ovale, atrial septal aneurysm, and right atrial anatomy among ischemic stroke patients. Stroke. 2003 Sep;34(9):2097-102.Full text Abstract
10. Levine BD, Grayburn PA, Voyles WF, et al. Intracardiac shunting across a patent foramen ovale may exacerbate hypoxemia in high-altitude pulmonary edema. Ann Intern Med. 1991 Apr 1;114(7):569-70. Abstract
11. Kerut EK, Norfleet WT, Plotnick GD, et al. Patent foramen ovale: a review of associated conditions and the impact of physiological size. J Am Coll Cardiol. 2001 Sep;38(3):613-23. Abstract
12. Mas JL, Zuber M. Recurrent cerebrovascular events in patients with patent foramen ovale, atrial septal aneurysm, or both and cryptogenic stroke or transient ischemic attack. Am Heart J. 1995 Nov;130(5):1083-8. Abstract
13. Wilmshurst PT, Pearson MJ, Nightingale S, et al. Inheritance of persistent foramen ovale and atrial septal defects and the relation to familial migraine with aura. Heart. 2004 Nov;90(11):1315-20. Abstract
14. Rigatelli G. Migraine and patent foramen ovale: connecting flight or one-way ticket? Expert Rev Neurother. 2008 Sep;8(9):1331-7. Abstract
15. Shanoudy H, Soliman A, Raggi P, et al. Prevalence of patent foramen ovale and its contribution to hypoxemia in patients with obstructive sleep apnea. Chest. 1998 Jan;113(1):91-6. Abstract
16. Silvestry FE, Cohen MS, Armsby LB, et al. Guidelines for the echocardiographic assessment of atrial septal defect and patent foramen ovale: from the American Society of Echocardiography and Society for Cardiac Angiography and Interventions. J Am Soc Echocardiogr. 2015 Aug;28(8):910-58.Full text Abstract
17. Rana BS, Thomas MR, Calvert PA, et al. Echocardiographic evaluation of patent foramen ovale prior to device closure. JACC Cardiovasc Imaging. 2010 Jul;3(7):749-60. Abstract
18. Angeli S, Del Sette M, Beelke M, et al. Transcranial Doppler in the diagnosis of cardiac patent foramen ovale. Neurol Sci. 2001 Oct;22(5):353-6. Abstract
19. Aggarwal K, Jayam VK, Meyer MA, et al. Thrombus-in-transit and paradoxical embolism. J Am Soc Echocardiogr. 2002 Sep;15(9):1021-2. Abstract
20. Schuchlenz HW, Weihs W, Beitzke A, et al. Transesophageal echocardiography for quantifying size of patent foramen ovale in patients with cryptogenic cerebrovascular events. Stroke. 2002 Jan;33(1):293-6.Full text Abstract
21. Earing MG, Cabalka AK, Seward JB, et al. Intracardiac echocardiographic guidance during transcatheter device closure of atrial septal defect and patent foramen ovale. Mayo Clin Proc. 2004 Jan;79(1):24-34. Abstract
22. Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association/American Stroke Association. Stroke. 2021 Jul;52(7):e364-467.Full text Abstract
23. National Health and Medical Research Council (Australia). Clinical guidelines for stroke management. 2021 [internet publication].Full text
24. National Institute for Health and Care Excellence. Percutaneous closure of patent foramen ovale to prevent recurrent cerebral embolic events. Dec 2013 [internet publication].Full text
25. Kuijpers T, Spencer FA, Siemieniuk RAC, et al. Patent foramen ovale closure, antiplatelet therapy or anticoagulation therapy alone for management of cryptogenic stroke? A clinical practice guideline. BMJ. 2018 Jul 25;362:k2515.Full text Abstract
26. Handke M, Harloff A, Olschewski M, et al. Patent foramen ovale and cryptogenic stroke in older patients. N Engl J Med. 2007 Nov 29;357(22):2262-8.Full text Abstract
27. Overell JR, Bone I, Lees KR. Interatrial septal abnormalities and stroke: a meta-analysis of case-control studies. Neurology. 2000 Oct 24;55(8):1172-9. Abstract
28. Messé SR, Gronseth GS, Kent DM, et al. Practice advisory update summary: patent foramen ovale and secondary stroke prevention: report of the Guideline Subcommittee of the American Academy of Neurology. Neurology. 2020 May 19;94(20):876-85.Full text Abstract
29. Pristipino C, Germonpré P, Toni D, et al. European position paper on the management of patients with patent foramen ovale. Part II - Decompression sickness, migraine, arterial deoxygenation syndromes and select high-risk clinical conditions. Eur Heart J. 2021 Apr 21;42(16):1545-53.Full text Abstract
30. National Institute for Health and Care Excellence. Percutaneous closure of patent foramen ovale for the secondary prevention of recurrent paradoxical embolism in divers. Dec 2010 [internet publication].Full text
31. O'Gara PT, Messe SR, Tuzcu EM, et al. Percutaneous device closure of patent foramen ovale for secondary stroke prevention: a call for completion of randomized clinical trials: a science advisory from the American Heart Association/American Stroke Association and the American College of Cardiology Foundation. Circulation. 2009 May 26;119(20):2743-7.Full text Abstract
32. Kitsios GD, Dahabreh IJ, Abu Dabrh AM, et al. Patent foramen ovale closure and medical treatments for secondary stroke prevention: a systematic review of observational and randomized evidence. Stroke. 2012 Feb;43(2):422-31. Abstract
33. Furlan AJ, Reisman M, Massaro J, et al; CLOSURE I Investigators. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med. 2012 Mar 15;366(11):991-9. Abstract
34. Meier B, Kalesan B, Mattle HP, et al. Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med. 2013 Mar 21;368(12):1083-91. Abstract
35. Bogousslavsky J, Garazi S, Jeanrenaud X, et al. Stroke recurrence in patients with patent foramen ovale: the Lausanne study. Neurology. 1996 May;46(5):1301-5. Abstract
36. Stone DA, Godard J, Corretti MC, et al. Patent foramen ovale: association between the degree of shunt by contrast transesophageal echocardiography and the risk of future ischemic neurologic events. Am Heart J. 1996 Jan;131(1):158-61. Abstract
37. Hung J, Landzberg MJ, Jenkins KJ, et al. Closure of patent foramen ovale for paradoxical emboli: intermediate-term risk of recurrent neurological events following transcatheter device placement. J Am Coll Cardiol. 2000 Apr;35(5):1311-6. Abstract
38. Homma S, Di Tullio MR, Sacco RL, et al. Surgical closure of patent foramen ovale in cryptogenic stroke patients. Stroke. 1997 Dec;28(12):2376-81.Full text Abstract
39. Pezzini A, Grassi M, Zotto ED, et al. Do common prothrombotic mutations influence the risk of cerebral ischaemia in patients with patent foramen ovale? Systematic review and meta-analysis. Thromb Haemost. 2009 May;101(5):813-7. Abstract
40. Dowson A, Mullen MJ, Peatfield R, et al. Migraine Intervention with STARFlex Technology (MIST) trial: a prospective, multicenter, double-blind, sham-controlled trial to evaluate the effectiveness of patent foramen ovale closure with STARFlex septal repair implant to resolve refractory migraine headache. Circulation. 2008 Mar 18;117(11):1397-404. Abstract
41. Kamineni R, Heuser R. Treatment of residual shunt after percutaneous closure of patent foramen ovale with a second Cardioseal device. Vasc Disease Manage. 2005 Jan-Feb;2(1):8-9.
42. Krumsdorf U, Ostermayer S, Billinger K, et al. Incidence and clinical course of thrombus formation on atrial septal defect and patent foramen ovale closure devices in 1,000 consecutive patients. J Am Coll Cardiol. 2004 Jan 21;43(2):302-9. Abstract
43. Delaney JW, Li JS, Rhodes JF. Major complications associated with transcatheter atrial septal occluder implantation: a review of the medical literature and the manufacturer and user facility device experience (MAUDE) database. Congenit Heart Dis. 2007 Jul-Aug;2(4):256-64. Abstract
Use of this content is subject to our disclaimer